Trial Profile
Phase I Trial of Maintenance Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Post Allogeneic Bone Marrow Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 08 Mar 2022 Status changed from active, no longer recruiting to completed.
- 01 Sep 2021 Results published in the Bone Marrow Transplantation
- 26 May 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.